4 225

Cited 60 times in

Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants

DC FieldValueLanguage
dc.contributor.author박경수-
dc.contributor.author박민수-
dc.contributor.author이동환-
dc.contributor.author이민구-
dc.contributor.author임아영-
dc.contributor.author정재용-
dc.contributor.author조성권-
dc.date.accessioned2014-12-20T16:28:04Z-
dc.date.available2014-12-20T16:28:04Z-
dc.date.issued2011-
dc.identifier.issn0009-9236-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/92771-
dc.description.abstractWe evaluated the effect of the pregnane X receptor (PXR) agonist rifampin on metformin pharmacokinetics, organic cation transporter 1 (OCT1) and OCT2 mRNA levels, and glucose levels, using the oral glucose tolerance test (OGTT) in 16 healthy subjects. The glucose-lowering effects of metformin were evaluated by OGTT before and after metformin treatment on days 1 and 2 and again on days 13 and 14 after a 10-day course of rifampin. Rifampin increased the difference in maximum glucose levels (ΔG(max)) by 41.9% (P = 0.024) and the area under the concentration-time curve (AUC) during the first 60 min after glucose ingestion (ΔAUC(gluc60)) by 54.5% (P = 0.020). Renal clearance (CL(R)) of metformin was increased by 16% (P = 0.008), but the systemic exposure was only slightly increased (13%, P = 0.049), possibly because of increased absorption. Rifampin increased OCT1 mRNA levels 4.1-fold in peripheral blood cells (P = 0.001); however, OCT2 mRNA was not detected. Our results suggest that rifampin increases OCT1 expression and hepatic uptake of metformin, leading to enhanced glucose-lowering action.-
dc.description.statementOfResponsibilityopen-
dc.format.extent416~421-
dc.relation.isPartOfCLINICAL PHARMACOLOGY & THERAPEUTICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAntibiotics, Antitubercular/pharmacology-
dc.subject.MESHArea Under Curve-
dc.subject.MESHBlood Glucose/drug effects-
dc.subject.MESHDrug Interactions-
dc.subject.MESHFemale-
dc.subject.MESHGlucose Tolerance Test-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents/pharmacokinetics*-
dc.subject.MESHHypoglycemic Agents/pharmacology-
dc.subject.MESHLiver/metabolism-
dc.subject.MESHMale-
dc.subject.MESHMetformin/pharmacokinetics*-
dc.subject.MESHMetformin/pharmacology-
dc.subject.MESHOctamer Transcription Factor-1/drug effects-
dc.subject.MESHOctamer Transcription Factor-1/genetics*-
dc.subject.MESHOrganic Cation Transport Proteins/drug effects-
dc.subject.MESHOrganic Cation Transport Proteins/genetics*-
dc.subject.MESHOrganic Cation Transporter 2-
dc.subject.MESHProspective Studies-
dc.subject.MESHRNA, Messenger/drug effects-
dc.subject.MESHRNA, Messenger/metabolism-
dc.subject.MESHReceptors, Steroid/agonists-
dc.subject.MESHRifampin/pharmacology*-
dc.subject.MESHTime Factors-
dc.subject.MESHYoung Adult-
dc.titleRifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pharmacology (약리학)-
dc.contributor.googleauthorS K Cho-
dc.contributor.googleauthorJ S Yoon-
dc.contributor.googleauthorM G Lee-
dc.contributor.googleauthorD H Lee-
dc.contributor.googleauthorL A Lim-
dc.contributor.googleauthorK Park-
dc.contributor.googleauthorM S Park-
dc.contributor.googleauthorJ-Y Chung-
dc.identifier.doi10.1038/clpt.2010.266-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01422-
dc.contributor.localIdA01468-
dc.contributor.localIdA02740-
dc.contributor.localIdA02781-
dc.contributor.localIdA03383-
dc.contributor.localIdA03709-
dc.contributor.localIdA03829-
dc.relation.journalcodeJ00608-
dc.identifier.eissn1532-6535-
dc.identifier.pmid21270793-
dc.identifier.urlhttp://www.nature.com/clpt/journal/v89/n3/full/clpt2010266a.html-
dc.contributor.alternativeNamePark, Kyung Soo-
dc.contributor.alternativeNamePark, Min Soo-
dc.contributor.alternativeNameLee, Dong Hwan-
dc.contributor.alternativeNameLee, Min Goo-
dc.contributor.alternativeNameLim, Lay Ahyoung-
dc.contributor.alternativeNameChung, Jae Yong-
dc.contributor.alternativeNameCho, Sung Kweon-
dc.contributor.affiliatedAuthorPark, Kyung Soo-
dc.contributor.affiliatedAuthorPark, Min Soo-
dc.contributor.affiliatedAuthorLee, Dong Hwan-
dc.contributor.affiliatedAuthorLee, Min Goo-
dc.contributor.affiliatedAuthorLim, Lay Ahyoung-
dc.contributor.affiliatedAuthorChung, Jae Yong-
dc.contributor.affiliatedAuthorCho, Sung Kweon-
dc.rights.accessRightsnot free-
dc.citation.volume89-
dc.citation.number3-
dc.citation.startPage416-
dc.citation.endPage421-
dc.identifier.bibliographicCitationCLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.89(3) : 416-421, 2011-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.